Index

ABUSE Digital health, risks, 20 Representations and warranties, in healthcare, 107	ALTERNATIVE DISPUTE RESOLUTION (ADR) —Cont'd Governs arbitration—Cont'd
AI See Artificial Intelligence	Mode of dispute resolution, only if the parties agree to it, 132
See Artificial Intelligence ALTERNATIVE DISPUTE RESOLUTION (ADR) Generally, 131 Allocating costs, 139 Attorneys' fees, 139 Award flexibility, 137 Baseball arbitration, 139 Choice Arbitration over court litigation Allocating costs, 139 Attorneys' fees, 139 Award flexibility, limiting, 137 Award flexibility, providing of, 137 Confidentiality, 137 Creative methods, baseball arbitration, 139 Expedited process, 135 Expert tribunal, 134 Finality, 135 Court litigation over arbitration, 139 Confidentiality, 137 Expedited process, 135	it, 132 Rules, 132, 134 Healthcare, 131 Tailoring ADR Allocation of fees, costs Considerations, 170 Options, 169 Recommendation, 170 Appeal clause Considerations, 172 Options, 171 Recommendations, 173 Applicable law Considerations, 148 Options, 148 Recommendations, 150 Applicable rules Considerations, 157 Options, 156 Recommendations, 158 Arbitrator selection Considerations, 159 Options, 158 Recommendations, 161 Award, form, scope Considerations, 167
Expert tribunal, 134	Options, 167 Recommendations, 168
Governs arbitration	Discovery, scope
Law, 132	Considerations, 164
Agreement, 132	Options, 163
Statutes, 133	Recommendations, 166

ALTERNATIVE DISPUTE RESOLUTION (ADR)	APPLICABLE LAWS AND GUIDANCE
—Cont'd	Artificial intelligence (AI)
Tailoring ADR—Cont'd	ASTP HT-1, 10
Mandatory ADR	EU AI Act, 14
Considerations, 143	Executive orders, 9
Options, 143	FDA guidance, discussion
Recommendations, 144	papers, and action plans,
Mediation	11
Considerations, 155	Generally, 9
Options, 154	ONC's HT-1, 10
Recommendations, 155	State legislation, 15
Opt-out ADR	Digital health, 7
Considerations, 143	ARTIFICIAL INTELLIGENCE
Options, 143	(AI)
Recommendations, 144	Generally, 3
Provider	ASTP's HT-1, 10
Considerations, 157	Bias, risk of, 23
Options, 156	Business practices, risk of, 21
Recommendations, 158	Compliance costs, risk of, 21
Scope of ADR clause	Definition, 3
Considerations, 152	Enforcement actions
Options, 152	See Enforcement Actions and
Recommendations, 153	Litigation EU AI Act, 14
Statement of purpose	Executive orders, 9
Considerations, 146	FDA guidance, discussion papers,
Options, 145	action plans, 11
Recommendations, 147	Governance, increased, 21
Venue	Intellectual property, risk of, 24
Considerations, 148	Liability, for healthcare providers,
Options, 148	21
Recommendations, 150	Litigation
ANTI-KICKBACK STATUTE	See Enforcement Actions and Litigation
Law influencing private equity, 46	Misinformation, risk of, 23
ANTITRUST ENFORCEMENT	ONC's HT-1, 10
	Privacy, risk of, 21
Agencies, 76	Regulators, 4
Law influencing private equity, 50	Risks
M&A policies, guidelines, 76	Bias, 23
Merger, 73	Changes to business practices,
Private equity, 50, 65	21
Trends in merger enforcement, 82	Generally, 20

ARTIFICIAL INTELLIGENCE	AWARD
(AI)—Cont'd	Alternative Dispute Resolution
Risks—Cont'd	(ADR)
Increased governance and	Flexibility, providing, 137
compliance costs, 21	Form of, 167
Intellectual property, 24	Scope, 167
Liability for healthcare providers, 21	BIAS
Misinformation, 23	Risks of artificial intelligence
Privacy, 21	(AI), 23
Security, 21	BURDEN OF PROOF
Security, risk of, 21	Clinical validation
State legislation, 15	Utilization management, the
State legislation, 13	treating physician rule, 504
ASTP HT-1	CHANGING HEALTHCARE
Applicable laws of AI, 10	SYSTEM SYSTEM
AUDIT	See Artificial Intelligence (AI)
Generally, 322	See Digital Health
Closing thoughts, 347	CLAIM ADJUSTMENT REASON
Defense	CODES (CARC)
Importance of audit defense,	Clinical validation
338	Development CARC and
Medicare appeals process, 334	RARC combination rules,
Employees regarding routing of	480
government communications,	Outcome of DRG and clinical validation, 478
342	Selection of CARC and RARC
Government healthcare audit	adjustment denial, 482
Auditors, 323	•
Audit Types, 327	CLINICAL VALIDATION
Identifying and returning overpay-	Accuracy through validation, 473
ments, 331	Clinical validation, 475 DRG validation, 473
60-day Rule, 331	Assigning ICD diagnosis and pro-
Inventory internal resources, 341	cedure codes to a medical
Meaningful internal audits, 345	record, 469
Medicare payment suspension, 329	Background, 464
Multi-disciplinary audit response	International Classifications of Diseases (ICD) and
team, 340	diagnostic related groups,
Proactive strategies for successful	467
audit defense, 340	Burden of proof
Targeted probe and educate audits,	Utilization management, the
328	treating physician rule, 504
Vigorously defend all denials, 343	Code assignment, 467

CLINICAL VALIDATION —Cont'd

Diagnostic Related Group (DRG), assigning, 470

Further examination

Clinical validation determinations and their classification, 487

DRG validation determinations and their classification, 485

Implications of clinical validation,

Clinical validation decisions as utilization review decisions, 500

Examination of the definition for the practice of medicine, 494

Review activities must be made using appropriate criteria, 499

Utilization review activities must be performed by qualified reviewers, 497

Validation in practice, clinical, 504

Introduction, 463

Outcome of DRG and clinical validation, 477

Claim Adjustment Reason codes (CARC)and Remittance Advice Remark Codes (RARC), 478

Development CARC and RARC combination rules,

Selection of CARC and RARC adjustment denial, 482

Transparency in health plan communication of DRG and clinical validation findings, 490

COMPULSION TEST

State actor, 245

DIGITAL HEALTH

Generally, 2

DIGITAL HEALTH—Cont'd

Abuse, 20

Applicable laws, 7

Corporate practice, risk of, 17

Definition, 2

Enforcement actions

See Enforcement Actions and Litigation

Fee-splitting, 18

Fraud, 20

Licensure, 18

Litigation

See Enforcement Actions and Litigation

Privacy, 19

Regulators, 4

ENFORCEMENT ACTIONS AND LITIGATION

Generally, in healthcare, 25 Department of Justice (DOJ), 26 Federal Trade Commission (FTC),

Food and Drug Administration (FDA), 26

Health and Human Services Office of Inspector General (HHSOIG), 26

EU AI ACT, 14

FALSE CLAIMS ACT

Reimbursement and payment Constitutionality of Qui Tam provision, 371

Damages, 385

Knowledge/scienter, 379

Pleading and proving falsity,

Pleading and proving materiality, 376

Public disclosure bar, 382

Retaliation, 388

Submission of claims and fraudulent scheme, 372

Index-4

INDEX

FOOD AND DRUG ADMINISTRATION (FDA) Artificial intelligence (AI) Applicable laws Action plans, 11 Discussion papers, 11 Guidance, 11	HEALTHCARE TRANSACTIONS—Cont'd Representations and warranties qualifiers—Cont'd Look-back periods, 115 Materiality qualifiers, 114 Survival periods, 117
Enforcement actions, 25 Litigation, 25 Digital health Enforcement actions, 25 Litigation, 25	HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA) Data privacy, law influencing
FRAUD	private equity, 48
Digital health, risks, 20 Healthcare fraud	JOINT VENTURES Reimbursement and payment, 219
Criminal enforcement, 390 Representations and warranties, in healthcare, 107	LICENSURE
HEALTHCARE PROVIDERS Risks of Artificial Intelligence (AI)	Digital health, risks, 18 Representations and warranties, in healthcare, 108
Liability for, 21	MEDICARE ENROLLMENT DEFENSES
HEALTHCARE	Advising clients
TRANSACTIONS Issues, transactional, 101	Allina in the defense context,
Representations and warranties Generally, 101	Escobar in the defense context, 437
Abuse, 107 Compliance with defined healthcare laws, 104 Definitions, 125 Evaluated parties, 100	Genera advice approach, 433 Legal defense approach, 434 Enrollment history, 426 2001 to 2009, 427
Excluded parties, 109 Fraud, 107 Licensure, 108	2010 and increased scrutiny, 427
Privacy, 110 Qualifiers, 113	Changes, enrollment form, 431 Introduction, 425
Regulatory compliance programs, 112	Practical advice real world scenarios, 454
Reimbursement, 105 Seller, of, 118	Harry does not work here anymore, 456
Representations and warranties	Lost in the mail, 457
qualifiers Knowledge qualifiers, 113	Reassignment whistleblower, 458

MEDICARE ENROLLMENT DEFENSES—Cont'd

Regulatory hierarchy overview,

Forms, 441

Manuals, 442

Why does the hierarchy matter?, 449

MISINFORMATION

Risks of artificial intelligence (AI), 23

MODERN PRIVATE EQUITY FIRMS

See private equity

NON COMPETES

American medical associations, 183

Argument for allowing non competes in healthcare, 187

Balance of competing interests, 176

Banning non competes in healthcare, 190

Harm to patients, 191

Harm to physicians, 190

Evolution in the United States, 179

Federal regulatory attempts to ban or restrict, 192

Federal Trade Commissions 2023 and 2024, 196

Future of non competes in healthcare, 204

Historical use, 176

Introduction, 176

NLRB 2023 and 2024

Attacks on non competes, 200

Non Competition Agreement, enforcement of, 176

Precursors to the FTCs 2024 final rule, 193

Rise and role of non competes,

State-level reforms to limit, 203

NON COMPETES—Cont'd

Use and the legal foundations, 176

OIG

Generally, 393

Early non face time services, 394

Care plan oversight, 398

Incident to, 394

Split/shared visits, 400

Enforcement risks given case law, 417

Allina, 420

Escobar, 418

Loper bright, 424

Today's coordination of care codes, 402

Advanced primary care

management services, 414

Chronic care management, 406

Remote physiologic monitoring,

Transitional care management, 403

ONC'S HT-1

Applicable laws of AI, 10

OVERPAYMENTS

Generally, 290

Considerations for different payor sources

Payments from

Federal health care program beneficiaries, 318

Medicaid FFS programs, 311

Medicare advantage organizations and medicaid managed care organizations, 314

Current lay of the land

The new rule, 282

Demise of reasonable diligence, 280

Down to brass tacks mechanics of the overpayments statute, 273 Look back period, 274

Index-6

OVERPAYMENTS—Cont'd	PRIVATE EQUITY IN THE
Down to brass tacks mechanics of	CROSSHAIRS
the overpayments statute, 273	Generally, 29
—Cont'd	Crosshairs, a framework for
Report and return requirement,	analyzing the four factors, 39
273	External factor influencing, 38
Federal Overpayment Statute, 265	
Identified, defined, 276	Four external factor influencing
Introduction, 264	Economics, 41
Landmark supreme court cases,	Cycles, 41
293	Inflation, 41
Allina, 297	Interest rates, impact of, 42
Escobar, 293	Limitations of the economic
Kisor, 308	view, 44
Loper Bright, 306	Law, legal, 45
Super Valu, 303	Anti-kickback statute, 46
Legal background and context,	Antitrust enforcement, 50
267	Corporate Practice of
Enforcement under the overpay-	Medicine (CPOM), 46
ment statute, 270	Data privacy, 48
Before the overpayment statute,	Health Insurance Portability
268	and Accountability Act
Takeaways for providers, 318	(HIPAA), 48
Trip down memory lane, 276	Limitations of the legal view, 53
PRIVACY	Post-closing liability (RWI),
Data privacy, HIPAA	52
See Health Insurance Portability	Stark law, 46
and Accountability Act	Philosophy
(HIPAA)	Disconnect from consumers,
Digital health, risks, 19	54
Representations and warranties, in	Ethics, 55
healthcare, 110	Innovation, ethics, 55
PRIVATE EQUITY	Limitations of the philosophi-
Federal litigation, 65	cal viewpoints, 56
Fund formation, operations	Politics
Capital deployment, 35	Disconnect from consumers,
Capital raising, 34	54
Formation, 33	Ethics, 55
Realization, 37	Innovation, ethics, 55
Structure, 33	Limitations of the political
Future, 57	viewpoints, 56
Modern private equity firms,	Temponius, 50
origin, 31	PUBLIC FUNCTION TEST
State legislation, evolving, 64	State actor, 244

REIMBURSEMENT AND	REIMBURSEMENT AND
PAYMENT	PAYMENT—Cont'd
Generally, 350	Enrollment, 220
Advantages	False Claims Act, developments
340B eligibility, 226	Constitutionality of Qui Tam
Access to hospital resources,	provision, 371
222	Damages, 385
Bad debt, 223	Knowledge/scienter, 379
Graduate medical education	Pleading and proving falsity,
payments, 224	374
Key considerations, 225	Pleading and proving material-
Residents working at	ity, 376
provider-based facilities,	Public disclosure bar, 382
225	Retaliation, 388
Higher reimbursement rates, 221	Submission of claims and fraudulent scheme, 372
Inclusion in the main providers	General nursing facility compli-
licensure contracts, 226	ance program, 351
Uncompensated care, 223	Healthcare fraud
Advisory opinions, OIG, 354	Criminal enforcement, 390
Anti Kickback Statute and Stark	Interaction with other payors, 234
Law, 351	Joint ventures, 219
Causation, 361	Management and under arrange-
Impact of loper bright, 365 Intent, 363	ment
Settlements	Contracts, 217
	OIG updates, 351
Hospital/physician kickback schemes, 366	Overview, 210
Settlements	Requirements for PBS, 212
Other, 368	Corporate structure and
CMS updates, 356	operational organization,
Overpayment rule revisions,	215
356	Location, 213
Self-referral disclosure protocol	Other considerations, 217
settlements, 359	Provision of services, 216
Disadvantages, 227	Public awareness, 217
Impact on off-campus provider	Special fraud alert on medicare
based facilities, 228	advantage marketing arrange-
Patient confusion and dissatis-	ments, 352
faction, 230	REMITTANCE ADVICE
Physician dissatisfaction, 231	REMARK CODES (RARC)
Site neutral payments, 227	Clinical validation
Stringent and complicated	Development CARC and
requirements with big con-	RARC combination rules,
sequences, 229	480

INDEX

STARK LAW Law influencing private equity, 46 Reimbursement Anti Kickback Statute and Stark Law, 351
Compulsion test, 245 Considerations for cases involving the state action requirement and MCO, 259 Entwinement test, 248 Public function test, 244 Section1983 General requirements, 241 Private parties, 242 State action joint action test, nexus, 246 State action requirement, 249
Decisions 2010, 253 2020, 258 Early 2000, 251 In the 1990, 250 Unique role of medicaid MCO in state medicaid programs, 239